Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August

TENAX THERAPEUTICS, INC.

Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).
Company expects to report topline data in August 2026; database lock and statistical analysis underway.
Trial evaluates TNX-103 (oral levosimendan) in PH-HFpEF; enrollment of >230 patients completed March 2026.
BSSR in Dec 2025 showed >90% power to detect 25m change in 6MWD primary endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.